<p>In the pharmaceutical industry, the strategic extension of drug exclusivity through polymorph patents presents a significant barrier to the timely market entry of generic competitors. This review delineates the use of pharmaceutical cocrystals as a sophisticated strategy to navigate these intellectual property hurdles. By forming a multi-component crystalline solid with a pharmaceutically acceptable co-former, a new solid form of the active pharmaceutical ingredient (API) is created, which is structurally and legally distinct from patented polymorphs. This approach provides a dual advantage: it offers a non-infringing pathway for generic development and simultaneously presents an opportunity to enhance the API's physicochemical properties. The formation of cocrystals can lead to significant improvements in solubility, dissolution rate, stability, and bioavailability, thereby creating value-added generic products with superior performance. This article examines the interplay between the Hatch–Waxman Act, regulatory pathways such as the ANDA, and the scientific principles of crystal engineering that underpin cocrystal design and synthesis. Through case studies of recently developed cocrystals for APIs like Daprodustat, Roxadustat, and Vadadustat, we illustrate the practical application and commercial potential of this strategy. Ultimately, pharmaceutical cocrystals represent a critical convergence of materials science, regulatory law, and drug delivery, offering an innovative and effective route for accelerating patient access to affordable and improved medicines.</p>